Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

Authors:

Abstract
The development of targeted therapies and immunotherapies has markedly advanced the treatment of metastasized melanoma. While treatment with selective BRAFV600E inhibitors (like vemurafenib or dabr...